Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine with docetaxel or cabazitaxel for metastatic castration-resistant prostate cancer
2024-518035-11-01Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eribulin in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in blood and urine Bis(monoacylglycero)phosphate (BMP). Planned start Dec 2024; status: authorised.
02
Drugs
eribulin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-518035-11-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518035-11-01.